This article is more than 5 years old. Information may no longer be current.
Study: Patients satisfied after taking denosumab, zoledronic acid to treat osteoporosis
Click Here to Manage Email Alerts
Patients taking denosumab to treat osteoporosis found a higher mean increase in spine bone mineral density, while patients treated with zoledronic acid had an increase in flu-like symptoms while taking the drug, according to researchers from Loyola University and the University of Notre Dame.
“Both groups of patients were satisfied with their treatment despite the discrepancies in the drugs,” Kellen Sheedy, a student at Stritch School of Medicine, stated in a press release.
Sheedy, Pauline Camacho, MD, and colleagues retrospectively analyzed 107 patients who were taking either denosumab or zoledronic acid for the treatment of osteoporosis, according to the abstract. The researchers reported no significant differences in femur T-score and bone mineral density, or spine T-score at 1 year. They also noted no significant differences in bone-specific alkaline phosphatase, back pain, muscle pain or patient satisfaction.
Kellen Sheedy
“This study helped us quantify the efficacy and adverse effects of these two drugs providing further guidance for physicians who prescribe these treatments,” Camacho, who is director of the Osteoporosis & Metabolic Bone Disease Center at Loyola University Health System, stated in a press release. “While this was the first head-to-head comparison of these two treatments, larger prospective studies will be needed to confirm these findings.”
Reference:
Sheedy K. Paper #MO0378. Presented at: the American Society for Bone and Mineral Research 2013 Annual Meeting; Oct. 4-7, 2013; Baltimore.
Disclosure: The authors have no relevant financial disclosures.